Please login to the form below

Not currently logged in
Email:
Password:

Asana appoints new chief medical officer

Louis Denis joins from Boehringer Ingelheim

Asana Biosciences has appointed Louis Denis as its new chief medical officer.

Denis is a medical oncologist with over 20 years of academic and industry experience in clinical cancer drug development.

He will be responsible for the overall strategic direction and medical oversight of clinical development of Asana's novel product candidates.

He said: “I am delighted to join Asana at this transformative time for the company.

“I look forward to working with the Asana team and its scientific advisory board to advance the company's broad portfolio of differentiated targeted therapies to help address major unmet medical needs.”

Denis has formerly held strategic and leadership positions at Boehringer-Ingelheim, where he headed the medical team, and Pfizer. 

Sandeep Gupta, president and chief executive officer of Asana Biosciences, said: “We are extremely pleased with the addition of Dr. Denis, a highly experienced physician and scientist, to our team. It represents a significant step in our evolution as an oncology-focused clinical development company.”

29th October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics